Associazione Nazionale Medici Cardiologi Ospedalieri

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
Effects of Alirocumab and Evolocumab on the outcomes and lipid profile of diabetic patients: Meta-analysis of randomized controlled trials.
Anno:
2023
Objective: To evaluate the specific effects of alirocumab and evolocumab on major cardiovascular events (MACE) and lipid profile in patients with diabetes. Methods: We conducted a systematic review of literature according to the PRISMA statement. A total of 8 randomized control trials (RCTs) enrolling 20651 patients with diabetes were included….
GESTIONE DELLA DISLIPIDEMIA E RIDUZIONE DEL RISCHIO CARDIOVASCOLARE GLOBALE NEI PAZIENTI AFFETTI DA HIV
Anno:
2023
Background: Presso il nostro ambulatorio cardiologico dedicato, afferiscono quotidianamente pazienti con infezione da HIV. Questa popolazione di pazienti è sottoposta con cadenza semestrale ad analisi ematochimiche di routine che comprendono anche l’assetto lipidico. Metodi: Sono stati arruolati in modo retrospettivo i pazienti con infezione da HIV afferenti all’ambulatorio cardiologico…
LOW-DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION IN PATIENTS AT VERY HIGH CARDIOVASCULAR RISK
Anno:
2023
Background: Guidelines of treatment of hypercholesterolemia in patients at very high cardiovascular (CV) risk have progressively lowered the target LDL-cholesterol (LDL-C). In real life LDL-C targets are difficult to reach. Aim of this study was to evaluate the achievement of LDL-C targets and the prescription of lipid-lowering therapy (LLT)…
Short term effectiveness of a novel nutraceutical for the management of hypercholesterolemia in patients with low to moderate cardiovascular risk: a multicenter primary care observational
Anno:
2023
Purpose: Increasing evidence reinforces the benefits of reduction of low-density lipoprotein (LDL-C) levels on cardiovascular outcomes. Different targets are suggested based on cardiovascular risk (CVR). According to the current European guidelines, a goal of LDL-C≤ 115mg/dL is desirable for patients with low-moderate CVR. However, a high percentage of these…
SMALL INTERFERING RNA: REAL-LIFE DATA WITH A NEW FRONTIER IN HYPOLIPIDEMIC THERAPY
Anno:
2023
Inclisiran (Leqvio® 284 mg) is a new small interfering RNA that acts on the mRNA coding for the gene PCSK9. Inclisiran is indicated in adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia as an adjunct to diet alone or in combination with a statin or other…
INFLAMMATION AND LIPID METABOLISM IN YOUNG PATIENTS WITH ACUTE CORONARY SYNDROME .
Anno:
2023
BACKGROUND: Inflammation and lipid metabolism play a central role in pathogenesis of atherosclerosis.  High sensitivity C-reactive protein (hsCRP), Lipoprotein(a) [Lp(a)] and other inflammation markers are well-established markers of cardiovascular (CV) diseases and are associated with adverse CV outcome after acute coronary syndrome (ACS). METHODS: The study enrolled patients ≤…
A possible role of a novel nutraceutical compound for IBS in triglycerides-lowering effect
Anno:
2023
In the last few years, growing evidence indicate that gut miocrobiome is linked to irritable bowel syndrome (IBS) and atherosclerotic disorders. The effect on lipid metabolism seems to be one of the potential mechanisms by which gut microbiome might favour the atherosclerotic process. IBS is a functional bowel disorder…